Bachem

BANB.SWPhase 2

Bubendorf, SwitzerlandFounded 1971bachem.com

Founded in 1971 and headquartered in Switzerland, Bachem has evolved from a specialized peptide laboratory into a global leader in TIDES manufacturing with over 1,200 employees worldwide. The company operates through an integrated platform covering clinical development, GMP manufacturing, and custom synthesis services for both peptides and oligonucleotides. With facilities in Switzerland, the US, and subsidiaries globally, Bachem serves as a trusted manufacturing partner to pharmaceutical and biotech companies developing innovative therapeutic products.

Market Cap

$5.9B

Founded

1971

Employees

1,200+

Focus

BiologicsPeptides

BANB.SW · Stock Price

USD 61.8536.85 (-37.34%)

Historical price data

AI Company Overview

Technology Platform

Integrated peptide and oligonucleotide development and manufacturing platform with over 50 years of expertise in TIDES synthesis, GMP manufacturing, and custom pharmaceutical services.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
ghrelin	Advanced Cancer	Phase 1/2

Funding History

Total raised: $110M

IPO$110MUndisclosedOct 6, 1998

Opportunities

Bachem is positioned to capitalize on the rapidly growing TIDES therapeutics market, with significant expansion opportunities in oligonucleotide manufacturing and global capacity increases.

The company's strategic goal of reaching CHF 1 billion in sales reflects the strong market demand for specialized peptide and oligonucleotide manufacturing services.

Risk Factors

Key risks include increasing competition in the CDMO space, stringent regulatory requirements for GMP manufacturing, and dependence on pharmaceutical industry cycles.

The company also faces challenges from raw material cost fluctuations and the need for continuous technology investment to maintain competitive advantages.

Competitive Landscape

Bachem competes in the specialized TIDES CDMO market against companies like PolyPeptide Group and CEM Corporation, with differentiation through its 50+ years of experience, integrated capabilities, and strong regulatory compliance. The company's expanding oligonucleotide capabilities and global manufacturing footprint provide competitive advantages in serving pharmaceutical partners.

Publications

Patents

Pipeline